Microbiome and Long COVID-19: Current Evidence and Insights
International Journal of Molecular Sciences · 17.10.2025 · 26 (20) · 10120
DOI: 10.3390/ijms262010120 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.10.2025. Verfasst von Olga A Caliman-Sturdza und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine and Biological Science, Stefan cel Mare University of Suceava, 720229 Suceava, Romania. Hauptthemen laut MEDLINE: COVID-19, Gastrointestinal Microbiome, Microbiota. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Romania's National Recovery and Resilience Plan, Ministry of Research, Innovation and Digitization under the Romania’s National Recovery and Resilience Plan Funded by the EU’s NextGenerationEU program.
Abstract (Originalsprache)
Long COVID, also referred to as post-acute sequelae of SARS-CoV-2 infection (PASC), is characterized by persistent multi-systemic symptoms such as fatigue, cognitive impairment, and respiratory dysfunction. Accumulating evidence indicates that gut and oral microbiota play an important role in its pathogenesis. Patients with long COVID consistently exhibit reduced microbial diversity, depletion of beneficial short-chain fatty acid (SCFA)-producing species such as Faecalibacterium prausnitzii and Bifidobacterium spp. and enrichment of proinflammatory taxa including Ruminococcus gnavus, Bacteroides vulgatus, and Veillonella. These alterations may disrupt intestinal barrier integrity, sustain low-grade systemic inflammation, and influence host immune and neuroendocrine pathways through the gut–brain and gut–lung axes. Distinct microbial signatures have also been associated with symptom clusters, including neuropsychiatric, respiratory, and gastrointestinal manifestations. Proposed mechanisms linking dysbiosis to long COVID include impaired SCFA metabolism, tryptophan depletion, microbial translocation, and interactions with host immune and inflammatory responses, including autoantibody formation and viral antigen persistence. Preliminary interventional studies using probiotics, synbiotics, and fecal microbiota transplantation suggest that microbiome-targeted therapies may alleviate symptoms, although evidence remains limited and heterogeneous. This review synthesizes current literature on the role of gut and oral microbiota in long COVID, highlights emerging microbial biomarkers, and discusses therapeutic implications. While causality remains to be firmly established, restoring microbial balance represents a promising avenue for diagnosis, prevention, and management of long COVID.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Medicine and Biological Science, Stefan cel Mare University of Suceava, 720229 Suceava, Romania.
- Emergency Clinical Hospital Suceava, 720224 Suceava, Romania.
- Department of Internal Medicine, Scripps Mercy Hospital, San Diego, CA 92103, USA.
ORCID-Profile: Olga A Caliman-Sturdza, Oana C Iatcu, Mihai Covasa
Förderung
- Romania's National Recovery and Resilience Plan
- Ministry of Research, Innovation and Digitization under the Romania’s National Recovery and Resilience Plan Funded by the EU’s NextGenerationEU program
Zitieren
APA
Caliman-Sturdza, O. A., Hamamah, S., Iatcu, O. C., Lobiuc, A., Bosancu, A., & Covasa, M. (2025). Microbiome and Long COVID-19: Current Evidence and Insights. International Journal of Molecular Sciences, 26(20), 10120. https://doi.org/10.3390/ijms262010120
Vancouver
Caliman-Sturdza OA, Hamamah S, Iatcu OC, Lobiuc A, Bosancu A, Covasa M. Microbiome and Long COVID-19: Current Evidence and Insights. International Journal of Molecular Sciences. 2025;26(20):10120. doi:10.3390/ijms262010120
BibTeX
@article{CalimanSturdza2025,
author = {Caliman-Sturdza, Olga A and Hamamah, Sevag and Iatcu, Oana C and Lobiuc, Andrei and Bosancu, Anca and Covasa, Mihai},
title = {Microbiome and Long COVID-19: Current Evidence and Insights},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {20},
pages = {10120},
doi = {10.3390/ijms262010120}
}
EUVIMED